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Real-world dataWe report a retrospective monocentric study performed on 63 patients affected by epilepsy with known
etiology, receiving perampanel as add-on therapy with at least 12-month follow-up. The purpose of our
study was to evaluate efficacy and tolerability of perampanel in this group of epilepsies. Patients were
classified into 2 groups based on the presence/absence of a single focal brain lesion on MRI, as epilepsy
etiology: 48 subjects were affected by focal lesional epilepsy and 15 by non-focal lesional epilepsy. The
retention rate was 76.2% and 53.9% at 12 and 24 months respectively. At 12 months, at least 40% of
patients resulted responders, with a significant reduction in seizure frequency (p = 0.01), confirmed at
24 months. Considering epilepsy etiology, we found a better PER response in patients with focal lesional
epilepsy. A significant correlation was observed between responder rates and EEG pattern. Only 30% of
patients reported mild-moderate adverse events. Efficacy and tolerability of PER, in our study, are in line
with the results reported in other real-world studies. Our data suggest the possibility of better PER
response in patients with focal brain lesions, which indicates that this drug could be a therapeutic option
in this population.
 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Epilepsy is one of the most common chronic neurological disor-
ders, affecting 1–2% of the general population worldwide [1].
Despite the availability of as many as 28 different anti-seizure
medications (ASMs) [2], up to 30% of epileptic patients remains
resistant to medical treatment [3].
The etiology of epilepsy is a strong prognostic predictor for sei-
zure recurrence and for subsequent drug-resistance. In particular,
people with epilepsies due to known etiology show a lower chance
of remission [4] and need long-term pharmacological treatment.Thus, it is important to identify safe, well-tolerated and effective
drugs, particularly in the setting of add-on therapy [4].
Perampanel (PER) is a non-competitive a-amino-3-hydroxy-5-
methyl-4-isoxazole-proprionic acid (AMPA) receptor antagonist.
Therapeutic efficacy and safety of PER had been demonstrated in
four phase III trials [5–8] and confirmed by several post-
marketing studies [9–11].
Our purpose was to evaluate both perampanel efficacy and tol-
erability, in a population with epilepsy due to known etiology, and
which type of seizure or epilepsy better responds to PER.
Material and methods
Study design
This is a retrospective monocentric long-term observational
study, conducted in a real-world setting. Patients were enrolled
among those attending the outpatient service of the Neurological
Unit of ‘‘Santa Maria della Misericordia” University Hospital in
Udine (Italy), between January 1st, 2015 and December 31st, 2018.
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with a known etiology; treatment with PER according to approved
indications; a clinical follow-up of at least 1 year. According to the
International League Against Epilepsy (ILAE) classification [12], we
considered epilepsies with known etiology including structural,
genetic, infectious, immune-mediated and metabolic causes. Diag-
nosis was made on clinical, electroencephalographic (EEG) and
neuroradiological features. For the analysis purpose, patients were
classified into two groups based on the presence or absence of a
single focal brain lesion on MRI, recognized as associated to epi-
lepsy. In particular, patients with a structural brain lesion were
included in the first group (defined as ‘‘focal lesional epilepsy”).
The second group (defined as ‘‘non-focal lesional epilepsy”) com-
prised patients with known etiology and negative MRI, and/or sub-
jects with known etiology and evidence of diffuse cerebral damage
at MRI.
Patients who did not attend regularly our outpatient service or
with unreliable clinical records were excluded.
Data collection
Data were collected from patients’ medical records and seizure
diaries.
The following data were collected at baseline: demographics,
age at epilepsy onset, epilepsy duration, seizure type, etiology,
number of concomitant and previous ASMs.
Seizure frequency was calculated at baseline, at visit (V) 6, V12
and, when possible, at V24, as mean seizures per month.
For the analysis, we considered beneficial effects lasting six
months or longer, to avoid regression to the mean [13].
During each visit, blood test (complete blood count and bio-
chemistry) was performed and data were extracted.
EEG recordings, performed in the 6 months before PER starting,
were collected.
Each EEG was performed during full wakefulness, with a 32-
channel machine (EB Neuro Mizar Sirius system with Galileo NT soft-
ware, EB Neuro), with electrodes placed according to the 10–20
International System. Recordings were routinely carried out for
20 minutes, with hyperventilation and photic stimulation. Low fre-
quency filter was set at 0.3 Hz, high frequency filter at 70 Hz; and
sensitivity was 70 microV/mm.
EEGs were separately analyzed off-line by two neurophysiolo-
gists (G. P. and A. N.). In case of discordance, a final review of
EEG traces was performed by the two neurophysiologists together,
until a common decision was obtained.
EEG recordings were scored according to the presence of slow
and/or epileptiform activity.
We identified 6 patterns:
1) unilateral focal slow theta activity;
2) unilateral focal slow theta activity with superimposed sharp
waves;
3) unilateral focal epileptiform activity;
4) bilateral focal epileptiform activity;
5) diffuse epileptiform activity;
6) normal (alpha rhythm as background without slow or
epileptic activity).
Study variables
The primary efficacy endpoints were: 1. the retention rate at
12 months and at 24 or more when applicable; 2. the proportion
of patients with 50% reduction in seizure frequency compared
to baseline (50% responder rate), observed at 12 and 24 months;
3. the proportion of patients free of all seizure types at 12 and
24 months. Secondarily, we considered the proportion of patients2
free of focal seizures and the proportion of subjects free from focal
to bilateral tonic-clonic seizures. Seizure freedom was defined as
the absence of seizures since the baseline visit, when PER was
started. Changes in seizure frequency at 12 and 24 months were
considered for the analysis.
Safety end points included: 1. the proportion of patients with
AEs at 6 and 12 months, and 24 months if available; 2. adverse
event (AE) severity, graded according to Common Terminology Cri-
teria for Adverse Events (CTCAE); 3. the proportion of patients with
AEs that lead to discontinuation at each visit.
Several clinical characteristics were compared: focal lesional
epilepsy vs. non-focal lesional epilepsy; focal seizures vs. focal to
bilateral tonic-clonic seizures; EEG patterns; early PER add-on
(0–2 previous ASMs, including current ASMs) vs. late PER add-on
(3 previous ASMs); patients receiving vs. not-receiving concomi-
tant enzyme-inducing ASMs (EiASMs).Statistical analysis
All data were collected in an ad hoc created database (Excel
2013, Microsoft Corp., Redmond, WA, USA). Data cleaning was per-
formed before the data analysis. The average imputation method
and the last observation carried forward method were used to han-
dle missing values (<5% of missing data).
Continuous variables were summarized by descriptive statis-
tics, expressed as median, arithmetic mean, standard deviation
and range, and categorical variables by absolute frequencies and
percentages.
In the efficacy analyses, variations in the frequency of seizures
were analyzed using Wilcoxon test for not normally distributed
data. For all subgroups analyses we used Chi-Square test (or Fish-
er’s exact test) to compare categorical variables, and McNemar test
for continuous variables.
Statistical analyses were performed using SPSS version 25 (IBM
Corporation, Chicago IL, USA).Results
Patients’ characteristics, disposition and retention rate
Sixty-four (72.7%) out of 88 patients receiving a prescription for
PER fulfilled the inclusion criteria. One patient was excluded
because of death due to disease progression (primary brain tumor),
3 months after starting PER therapy.
Among the 63 enrolled patients (32 females and 31 males,
mean age at PER onset: 45.8 ± 12.8 years, age range: 21–76 years),
48 (76.2%) were affected by epilepsy due to focal lesion, while 15
(23.8%) by non-focal lesional epilepsy.
Main demographic variables and etiology are reported in the
Table 1.
All patients had a 12 months clinical follow-up; for 39 of them
(61.9%) a follow-up of 2 years was also available.
The retention rate was 76.2% and 53.9% at 12 and 24 months
respectively.
The mean (±SD) perampanel dose was 5.9 ± 1.93 mg at
6 months, 6.9 ± 1.85 mg at 12 months and 7.8 ± 1.98 mg at
24 months. Subjects taking at least one EiASMs at the time of
PER initiation attained a higher maximum perampanel dose com-
pared to those with a non-EiASMs (7 mg vs. 5.9 mg, respectively,
p = 0.04).
The mean duration of perampanel exposure was 23.7 ± 14.06
months (range: 6–48 months).
At 12-months follow-up, 15 patients discontinued PER, while at
24-months 5 more patients withdrew the drug.
Table 1






Median age at epilepsy onset, years (IQR) 18 (0–72)
Median duration of epilepsy, years (IQR) 26 (1–60)
Mean age at perampanel onset, years (range) 45.8 (21–76)
Median number of previous (excluding current) ASMs (IQR) 3 (0–9)
Median number of concomitant ASMs (IQR) 2 (1–5)
Early add-on, n (%) 14 (22.2)
Late add-on, n (%) 49 (77.8)
Concomitant EiASMs, n (%) 34 (54)
1 EiASMs 26 (41.3)
>1 EiASMs 8 (12.7)
Concomitant non-EiASMs, n (%) 29 (46)
Epilepsy with known etiology, classification
Focal lesional epilepsy, n (%) 48 (76.2)
Cortical malformations 23 (36.5)
Arteriovenous malformations 3 (4.8)
Tumor-related 13 (20.6)
Post-traumatic 9 (14.3)
Non-focal lesional epilepsy, n (%) 15 (23.8)
Diffuse cerebral microangiopathy 8 (12.7)
Genetic (channelopathies) 3 (4.7)
Infective 2 (3.2)
Immune (Ab anti-CASPR2 and anti-LGI1) 2 (3.2)
Temporal lobe epilepsy, n (%) 28 (44.4)
Non-temporal lobe epilepsy, n (%) 35 (55.6)
Seizure type at PER onset, n (%)
Focal seizures 32 (50.8)
Focal to bilateral tonic-clonic seizures 6 (9.5)
Focal seizures + focal to bilateral tonic-clonic seizures 25 (39.7)
Legend: IQR = interquartile range; ASMs = antiseizure medications; EiASMs = en-
zyme-inducing antiseizure medications.
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occurrence of AEs (5 patients) and both conditions (5 subjects).Treatment response
Seizure frequency change and response
At 12 months, 39.7% (25/63) of subjects showed a significant
reduction in all seizure frequency (p = 0.01, Wilcoxon test) with
an average relative reduction in seizure frequency of 35.7%. Ten
patients (15.7%) were seizure-free. This statistically significant
reduction of seizure frequency was confirmed at 24 months
(p = 0.001, Wilcoxon test). After 24 months of treatment, 9 patients
were seizure-free and 13 subjects (33.4%) showed a reduction of
seizure frequency  50%.
A sub-analysis of seizure types showed a significant reduction
of both focal seizures and focal to bilateral tonic-clonic seizures
frequency from baseline to 12 months (p = 0.002 and p = 0.005,
respectively, Wilcoxon test). At 24 months, only focal to bilateral
tonic-clonic seizures retained a significant reduction in frequency
(p = 0.01) (Fig. 1). Focal to bilateral tonic-clonic seizures displayed
a better trend to improve then focal seizures, both at 12 and
24 months (p = 0.06, McNemar test).
Considering the etiology of epilepsies, patients with a brain
focal lesion showed a better PER response at 12 and 24 months
(p = 0.03 and p = 0.02 respectively, Chi-square test) as showed in
Table 2.
Focusing on specific clinical variables, we observed better sei-
zure outcomes in patients with epilepsy duration < 20 years
(p = 0.02, Chi-square test), and in patients who took PER as early
add-on (p = 0.02, Chi-square test).
At 12 months, the efficacy of PER was greater in association
with the use of concomitant non-EiASMs (p = 0.05, Fisher’s test).3
EEG patterns
Unilateral focal epileptiform activity (pattern 3) was the most
frequently observed in our sample (36.5%, 23/63). Several patients
presented a combination of 2 different EEG patterns. Pattern 2
(unilateral focal slow theta activity with superimposed sharp
waves) was significantly associated to a better responder rate, both
at 12 and 24 months of follow-up (p = 0.005 and p = 0.01 respec-
tively, Fisher’s exact test).
Stratifying patients on the basis of etiology and comparing the
etiology to EEG patterns, we found that pattern 2 was present only
in patients with focal lesional epilepsy: 7 patients with tumor-
related epilepsy, 6 with epilepsy associated to cerebral malforma-
tions and 3 with post-traumatic epilepsy. An additional sub-
analysis was performed and it showed a better, even if not statis-
tically significant, seizures outcome in patients with tumor-
related epilepsy (p = 0.09, Fisher’s exact test). The distribution of
EEG patterns and seizures outcome are summarized in Table 3.Safety and tolerability
By 12 months, 30.2% (19/63) of patients had reported at least
one AE, and seven of them (11.1%) at least 2 different AEs. Most
AEs occurred within the first 3–6 months of therapy (16/63,
25.4%). In fact, at 24 months, only three additional patients experi-
enced a late AE.
All reported AEs were mild (grade 1) or moderate (grade 2), like
irritability (17.2%), psychomotor delay (25.8%) and dizziness
(17.2%). Only one patient experienced a grade 3 AE, consisting in
a cutaneous rash that remitted after PER discontinuation. Severe
psychiatric symptoms were not reported. The rate of psychiatric
AEs was not statistically increased in patients taking topiramate
or levetiracetam or both, compared to other drug combinations.
No alterations of laboratory parameters have been observed.
The incidence of AEs was significantly influenced only by the
use or not of concomitant EiASMs (p = 0.04, Chi-square test).Discussion
We investigated the efficacy and safety of PER in a retrospective
real-life study, finding that patients with focal lesional epilepsy
and those with a specific EEG pattern (unilateral focal slow theta
activity with superimposed sharp waves) represent the group
more likely to benefit from this ASM. These findings are relevant
as they address a common clinical problem, namely the manage-
ment of lesional epilepsy, which is complicated by polytherapy,
drug-to-drug interactions, limitations in ASMs use and comorbidi-
ties. The direct consequence of these issues is a greater intrinsic
risk of drug-resistance and AEs development, which strongly
affects the therapeutic choice, thus calling attention on a more
‘‘targeted” approach. In addition, our study shows the overall effi-
cacy and safety of PER, providing also a higher retention rate (76.2%
and 53.9% at 12 and 24 months, respectively) as compared to pre-
vious real-world studies (50.5% to 60.6%) [11,14,15], despite a
lower mean dose of the drug [11,14,15]. A statistically significant
reduction of seizure frequency both at 12 and 24 months was
observed. Seizure freedom was achieved in 15.7% patients at
12 months and in 14.3% patients at 2 years. As reported in the ran-
domized controlled trials (RCTs) [5–8] and in two real-world stud-
ies [11,16], focal to bilateral tonic-clonic seizures showed a better
clinical response maintaining a statistically significant improve-
ment at 12 and 24 months. This could be explained by the reduc-
tion of seizure propagation due to the antagonism of AMPA
receptor exerted by PER [17] and it may suggest the use of peram-
panel in patients with focal to bilateral tonic-clonic seizures.
Greater efficacy of PER in focal lesional epilepsy may depend on
Fig. 1. Changes in seizure frequency/mos with perampanel at 12 and 24 months relative to baseline by seizure type.
Table 2













Responder rate 17 (26.9%) 8 (12.7%) 13 (33.4%) 9 (23.0%)
Responder 50–99% 8 (12.7%) 7 (11.2%) 5 (12.8%) 8 (20.5%)
Seizure-free 9 (14.2%) 1 (1.5%) 8 (20.5%) 1 (2.5%)
Non Responder 31 (49.1%) 7 (11.2%) 12 (30.8%) 5 (12.8%)
Total 48 15 25 14
Table 3
EEG patterns and responders’ correlations.
Pattern EEG n (%) Responders
(total n = 25)
12 months
Responders
(total n = 22)
24 months
n (%) p-value n (%) p-value
Type 1 17 (26.9) 6 (24) 0.76 5 (22.7) 0.55
Type 2 16 (25.4) 10 (40) 0.005a 9 (40.9) 0.01a
Type 3 23 (36.5) 5 (20) 0.17 4 (18.3) 0.21
Type 4 6 (9.5) 3 (12) 0.23 2 (9.1) 0.29
Type 5 6 (9.5) 1 (4) 0.38 1 (4.5) 0.23
Type 6 7 (11.2) 0 (0) 0.72 1 (4.5) 0.42
a Fisher’s exact test: statistically significant.
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nisms of tumor-related epilepsy, post-traumatic epilepsy and
structural temporal lobe epilepsy, as demonstrated by preclinical
and clinical evidences [18–20]. In fact, in brain tumor-related epi-
lepsy, alteration of glutamate homeostasis induces an increased
excitotoxicity which promotes migration and expression of tumor
cells. Moreover, increased glutamate production leads to neuronal
hyperexcitability in the neural tissue surrounding the tumor; all4
these processes contribute to maintain and propagate epileptic
activity [18–19]. Glutamate plays a central role also in the patho-
physiology of traumatic brain injury and subsequent process of
epileptogenesis [21].
Finally, our data indicate that PER was globally well tolerated,
with side effects which tend to subside over time. Concomitant
use of non-EiASMs emerged as the only risk factor for increased
AEs rate.
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This is a retrospective study, thus it presents all limitations
intrinsic to this kind of observations (lack of randomization and
control group, risk of missing relevant information). We acknowl-
edge that the sample is limited, since we focused on epilepsy due
to known etiology.
Moreover, we considered a different and heterogeneous type of
etiology that limits the generalization of our results.
Finally, it comes from a single center, a guarantee of homogene-
ity, but also a risk of unintended biases.
Conclusions
Our study suggests that patients with focal lesional epilepsy
and those with a distinct EEG pattern (unilateral focal theta activ-
ity with superimposed sharp waves) may represent the group most
likely to favorably respond to PER. These results need future vali-
dation in multicenter trials adopting a clinical stratification based
on neuroimaging and EEG data.
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